| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
For the Quarter Ended September 30, 2026 |
|
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
|
$ |
219,691 |
|
$ |
80,164 |
|
$ |
299,855 |
Intersegment |
|
|
|
|
|
|
|
|
(143) |
Consolidated net sales |
|
|
|
|
|
|
|
$ |
299,712 |
Segment operating income |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
57,592 |
|
|
34,503 |
|
|
|
Selling, general and administrative |
|
|
63,001 |
|
|
29,317 |
|
|
|
Research and development |
|
|
15,900 |
|
|
10,447 |
|
|
|
Segment operating income |
|
$ |
83,198 |
|
$ |
5,897 |
|
$ |
89,095 |
Unallocated amounts |
|
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
|
(14,663) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
|
(17,760) |
Certain litigation charges |
|
|
|
|
|
|
|
|
(46) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
|
(14,757) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
|
(3,838) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
|
(1,428) |
Consolidated operating income |
|
|
|
|
|
|
|
$ |
36,603 |
|
|
|
|
|
|
|
|
|
|
For the Quarter Ended September 30, 2025 |
|
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
|
$ |
202,188 |
|
$ |
79,458 |
|
$ |
281,646 |
Other revenue(1) |
|
|
|
|
|
|
|
|
5,439 |
Intersegment |
|
|
|
|
|
|
|
|
(530) |
Consolidated net sales |
|
|
|
|
|
|
|
$ |
286,555 |
Segment operating income |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
|
50,518 |
|
|
33,737 |
|
|
|
Selling, general and administrative |
|
|
59,766 |
|
|
27,851 |
|
|
|
Research and development |
|
|
14,191 |
|
|
8,992 |
|
|
|
Segment operating income |
|
$ |
77,713 |
|
$ |
8,878 |
|
$ |
86,591 |
Unallocated amounts |
|
|
|
|
|
|
|
|
|
Amortization of intangibles |
|
|
|
|
|
|
|
|
(15,350) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
|
(3,351) |
Certain litigation charges |
|
|
|
|
|
|
|
|
(2,408) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
|
(12,096) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
|
(7,511) |
Recovery of assets held-for-sale |
|
|
|
|
|
|
|
|
6,789 |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
|
(2,433) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
|
(2,573) |
Consolidated operating income |
|
|
|
|
|
|
|
$ |
47,658 |
(1)Includes the quarterly results of a business that has met the held-for-sale criteria as of June 30, 2025.
|